AstraZeneca PLC (AZN)vsMoolec Science SA Ordinary Shares (MLEC)
AZN
AstraZeneca PLC
$185.95
-0.79%
HEALTHCARE · Cap: $282.69B
MLEC
Moolec Science SA Ordinary Shares
$8.10
+18.59%
HEALTHCARE · Cap: $5.27M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 771504% more annual revenue ($60.44B vs $7.83M). AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
MLEC
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Intrinsic value data unavailable for MLEC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Revenue surging 948.0% year-over-year
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Trading at 11.6x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : MLEC
The strongest argument for MLEC centers on Revenue Growth. Revenue growth of 948.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : MLEC
The primary concerns for MLEC are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 7.21 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while MLEC is a hypergrowth play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.21 — expect wider price swings.
MLEC is growing revenue faster at 948.0% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 44/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Moolec Science SA Ordinary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company is headquartered in Luxembourg.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?